Phase 1 study of FT-2102, an inhibitor of mutant IDH1, in patients with relapsed/refractory IDH1 mutant gliomas: Preliminary safety and clinical activity

Authors
Category Primary study
JournalNeuro-Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 0fe33eac2f42ae5dabdc940cdcc73a181a8dd446
First added on: Feb 11, 2025